Cerity Partners’s Neurogene NGNE Stock Holding History

Cerity Partners’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,550	Closed	-$286K	–	713
2021 Q2	$286K	Hold	1,550	–	–	0.01%	596
2021 Q1	$382K	Buy	+1,550	New	+$396K	0.01%	498

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Cerity Partners's NGNE Position: Q3 2021 in Review

Cerity Partners sold out of Neurogene (NGNE) in Q3 2021, closing a stake of 1,550 shares — an estimated $286K sold.

Cerity Partners first reported a position in NGNE in Q1 2021 and held it in 2 quarters. The position peaked at $382K in Q1 2021. 85 funds tracked by Wall St. Rank hold NGNE as of Q3 2021.

Cerity Partners reported no remaining Neurogene position as of Q3 2021 after selling out during the quarter.
Cerity Partners sold 1,550 Neurogene shares in Q3 2021, an estimated $286K.
Cerity Partners first reported a position in Neurogene in Q1 2021 and held it in 2 quarters.
Cerity Partners's Neurogene position peaked at $382K in Q1 2021.
85 funds tracked by Wall St. Rank held Neurogene as of Q3 2021.

Based on Cerity Partners's 13F filing for Q3 2021, filed 25 Oct 2021.